Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $31.81 Consensus Price Target from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the sixteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $31.81.

NRIX has been the topic of several recent analyst reports. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $35.00 target price on the stock. HC Wainwright boosted their target price on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Royal Bank of Canada boosted their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Stephens restated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, BTIG Research initiated coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 target price on the stock.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company's stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by insiders.

Remove Ads

Institutional Trading of Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Nurix Therapeutics by 14.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 146,713 shares of the company's stock valued at $2,764,000 after acquiring an additional 18,189 shares during the last quarter. Woodline Partners LP increased its stake in Nurix Therapeutics by 0.5% during the 4th quarter. Woodline Partners LP now owns 338,462 shares of the company's stock worth $6,377,000 after purchasing an additional 1,583 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $1,844,000. Finally, Vestal Point Capital LP increased its stake in Nurix Therapeutics by 14.1% during the 4th quarter. Vestal Point Capital LP now owns 485,000 shares of the company's stock worth $9,137,000 after purchasing an additional 60,000 shares in the last quarter.

Nurix Therapeutics Stock Up 0.1 %

NRIX traded up $0.01 during trading on Friday, reaching $14.27. 714,888 shares of the company's stock were exchanged, compared to its average volume of 878,959. Nurix Therapeutics has a fifty-two week low of $11.90 and a fifty-two week high of $29.56. The business has a 50 day moving average price of $18.30 and a 200 day moving average price of $21.67. The company has a market capitalization of $1.08 billion, a P/E ratio of -4.94 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. As a group, research analysts forecast that Nurix Therapeutics will post -2.99 EPS for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.